Focus Partners Wealth
ALDX icon

Focus Partners Wealth’s Aldeyra Therapeutics ALDX Stock Holding History

Focus Partners Wealth’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5K Sell
13,863
-8,235
-37% -$14.2K ﹤0.01% 2711
2026
Q1 		$37.3K Buy
+22,098
New +$96.8K ﹤0.01% 2593

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Focus Partners Wealth's ALDX Position: Q2 2026 in Review

Focus Partners Wealth reduced its Aldeyra Therapeutics (ALDX) stake by 37% in Q2 2026, selling an estimated $14.2K and leaving 13,863 shares worth $29.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2711.

Focus Partners Wealth first reported a position in ALDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $37.3K in Q1 2026. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Focus Partners Wealth held 13,863 shares of Aldeyra Therapeutics worth $29.5K as of Q2 2026.
  • Focus Partners Wealth sold 8,235 Aldeyra Therapeutics shares in Q2 2026, an estimated $14.2K.
  • Aldeyra Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2711 holding.
  • Focus Partners Wealth first reported a position in Aldeyra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Focus Partners Wealth's Aldeyra Therapeutics position peaked at $37.3K in Q1 2026.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.